Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Br J Haematol
    November 2026
  1. STOMPER J, Kicinski M, Ma T, Meyer T, et al
    Increase in fetal haemoglobin from baseline to day 10 is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC Leukemia Group, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) and German
    Br J Haematol. 2026 Nov 3. doi: 10.1111/bjh.70874.
    >> Share

    October 2026
  2. KISLOVA M, Dmitrieva E, Naumova E, Pochtar M, et al
    Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype.
    Br J Haematol. 2026;209:1664-1672.
    >> Share

  3. KUNADT D, Zukunft S, Rollig C, Metzelder S, et al
    Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.
    Br J Haematol. 2026;209:1783-1796.
    >> Share

  4. PALMIERI R, Piciocchi A, Soddu S, Frigeni M, et al
    Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.
    Br J Haematol. 2026;209:1735-1745.
    >> Share

  5. LIU R, Li B, Zhang J, Xu W, et al
    Multiparameter flow cytometry versus droplet digital polymerase chain reaction for monitoring measurable residual disease in paediatric fusion gene-positive acute myeloid leukaemia.
    Br J Haematol. 2026;209:1562-1573.
    >> Share

  6. MURAYAMA E, Kawai T, Yamato G, Shiba N, et al
    Multiomics analysis focusing on genome-wide DNA methylation in paediatric acute promyelocytic leukaemia.
    Br J Haematol. 2026;209:1586-1597.
    >> Share

  7. TIZRO P, Aldoss I, Wang X, Kwak LW, et al
    B-cell activating factor receptor expression in B-lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy.
    Br J Haematol. 2026;209:1530-1537.
    >> Share

  8. GAO J, Qiu H, Tong Y, Huang C, et al
    Venetoclax-enhanced reduced-intensity conditioning in older patients aged >/=55 years with high-risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study.
    Br J Haematol. 2026;209:1773-1782.
    >> Share

    September 2026
  9. ROSEN N, Rodriguez-Real G, Vom Stein AF, Schreurs LD, et al
    Reduced colony-stimulating factor 1 receptor expression in myeloid cells has limited impact on chronic lymphocytic leukaemia progression.
    Br J Haematol. 2026;209:939-952.
    >> Share

  10. YANG Y, Tang Y, Yang K, Zhang Y, et al
    CCAAT/enhancer-binding protein alpha basic leucine zipper in-frame insertion/deletion (CEBPA bZIP-InDel-inf) defines a favourable-prognosis subgroup in CEBPA-mutated acute myeloid leukaemia.
    Br J Haematol. 2026;209:1136-1145.
    >> Share

  11. CHAN WY, Al-Yousuf H, Lam HPJ, Leong S, et al
    Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience.
    Br J Haematol. 2026;209:1386-1390.
    >> Share

  12. SHIMIZU K, Saito MK, Maringe C, Miyazaki Y, et al
    Socioeconomic inequality in treatment of acute myeloid leukaemia (AML) in England, 2015-2022: A population-based study.
    Br J Haematol. 2026;209:1128-1135.
    >> Share

  13. LIU Q, Wang X, Fan J, Zheng Y, et al
    DHX15 affects AML1-ETO9a splicing together with HNRNPL, RBM33 in AML1-ETO-positive acute myeloid leukaemia.
    Br J Haematol. 2026;209:964-977.
    >> Share

  14. KHAN A, Gajendra S, Rai S, Thakral D, et al
    Leukaemic stem cell burden enhances prognostic precision in the non-adverse European LeukemiaNet risk group of acute myeloid leukaemia.
    Br J Haematol. 2026;209:1119-1127.
    >> Share

  15. DUMINUCO A, Leotta D, Allegra A, Caracciolo D, et al
    Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.
    Br J Haematol. 2026;209:1010-1019.
    >> Share

  16. PLAYA-ALBINYANA H, Giro A, Pineyroa JA, Araujo-Ayala F, et al
    Scaffold-free three-dimensional culture of chronic lymphocytic leukaemia preserves B-T-cell cross-talk and enables drug response profiling.
    Br J Haematol. 2026;209:953-963.
    >> Share

  17. RUI M, Cheung YT, Zhang H, Wei Q, et al
    Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost-effectiveness analysis.
    Br J Haematol. 2026;209:1146-1157.
    >> Share

    August 2026
  18. HERMANSEN JU, Yin Y, Tjonnfjord GE, Mato AR, et al
    Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia.
    Br J Haematol. 2026;209:469-479.
    >> Share

  19. INFANTE JB, Aguiar E, Sa I, Marques I, et al
    Improved real-world outcomes of patients with acute promyelocytic leukaemia treated with first-line arsenic trioxide in specialized centres in Portugal through a 24/7 phone-based referral.
    Br J Haematol. 2026;209:804-808.
    >> Share

  20. GUPTA G, Podolsky S, Liu N, Cheung MC, et al
    Frailty and health resource utilization in 5450 adults with acute myeloid leukaemia: A population-based study from Ontario, Canada.
    Br J Haematol. 2026;209:601-609.
    >> Share

  21. CONNERTY P, Colgan JN, El-Najjar F, Henry E, et al
    The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia.
    Br J Haematol. 2026;209:491-502.
    >> Share

  22. JIMENEZ-MIRA C, Tovar N, Martinez-Cibrian N, Gonzalez-Calle V, et al
    Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.
    Br J Haematol. 2026;209:610-620.
    >> Share

  23. LI R, Yao Y, Yang D, Mao L, et al
    Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyrib
    Br J Haematol. 2026;209:642-652.
    >> Share

  24. BOBERG E, Lubking A, Lennmyr EB, Dietrich CE, et al
    Central nervous system involvement and relapse in adult acute lymphoblastic leukaemia-a population-based analysis in 2007-2022.
    Br J Haematol. 2026;209:589-600.
    >> Share

  25. WANG H, Xue J, Yan W, Gao Y, et al
    Identification of GSE1 as a PAX5 fusion partner and characterization of PAX5 fusion signature in B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2026;209:480-490.
    >> Share

  26. ISHIDA H, Okamoto Y, Sakaguchi H, Arai Y, et al
    Transplantation outcomes in patients with Down syndrome-associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies.
    Br J Haematol. 2026;209:632-641.
    >> Share

    July 2026
  27. IRIYAMA N, Takahashi N, Fujimaki K, Ono T, et al
    Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.
    Br J Haematol. 2026 Jul 9. doi: 10.1111/bjh.70678.
    >> Share

  28. ZHOU J, Kui X, Huang D, Zhang X, et al
    AKT inhibitor capivasertib reverses EVI1-driven resistance to venetoclax in acute myeloid leukaemia.
    Br J Haematol. 2026;209:84-95.
    >> Share

  29. BHATIA P, Sharun S, Palla S, Brady SW, et al
    Acquired thiopurine resistance and mismatch repair aberrations in paediatric B-cell acute lymphoblastic leukaemia relapse: A real-world data integrating mutational signatures, clones and clinical thiopurine dosing patterns.
    Br J Haematol. 2026;209:54-62.
    >> Share

  30. FERRARA F
    Azacitidine-venetoclax in unfit acute myeloid leukaemia: One size does not fit all.
    Br J Haematol. 2026;209:391-392.
    >> Share

  31. RAMPOTAS A, Naylor-Layland G, Brown C, Alabdulkarim A, et al
    Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.
    Br J Haematol. 2026;209:160-171.
    >> Share

  32. ZHANG ZX, Zhang L, Lu AD, Zhang LP, et al
    Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.
    Br J Haematol. 2026;209:172-179.
    >> Share

  33. TODA Y, Jo T, Arai Y, Harada K, et al
    Impact of CD34(+) cell dose on outcomes of related allogeneic PBSCT in adult AML patients.
    Br J Haematol. 2026;209:210-221.
    >> Share

  34. KATSIMIGAS A, Werling M, Frederiksen CM, Vainer N, et al
    Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort.
    Br J Haematol. 2026 Jul 1. doi: 10.1111/bjh.70651.
    >> Share

    June 2026
  35. ITONAGA H, Fukushima T, Kato K, Muranushi H, et al
    Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience.
    Br J Haematol. 2026 Jun 15. doi: 10.1111/bjh.70631.
    >> Share

  36. CHRISTENSEN LM, Simonsen MR, Jensen JF, Kristensen DT, et al
    Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: A population-based study using the WHO 2022 classification.
    Br J Haematol. 2026;208:2104-2112.
    >> Share

    May 2026
  37. CHENG Q, Zhu Y, Sheng K, Zhou J, et al
    Long-term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T-lymphoblastic lymphoma.
    Br J Haematol. 2026 May 24. doi: 10.1111/bjh.70581.
    >> Share

  38. ALLSUP DJ, Cairns DA, Samy EF, Duley L, et al
    Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.
    Br J Haematol. 2026;208:1596-1607.
    >> Share

  39. GEORGE A, Rolf E, Domeradzka M, Ribeiro S, et al
    Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants.
    Br J Haematol. 2026;208:1584-1595.
    >> Share

  40. KALAMPALIKA F, Jimenez-Pompa A, Sanchez-Lanzas R, Patel B, et al
    Chemotherapy-driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia.
    Br J Haematol. 2026;208:1572-1583.
    >> Share

  41. COWELL JK, Fang X, Mori SF, Hu T, et al
    An oncogenic, truncated FGFR1 variant cooperates with SPFQ/NONO to regulate gene transcription in FGFR1-driven leukaemia.
    Br J Haematol. 2026;208:1564-1571.
    >> Share

  42. SCOTT AP, Lo A, Xia Y, Thompson K, et al
    Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy.
    Br J Haematol. 2026;208:1692-1703.
    >> Share

  43. COSTA A, Scalzulli E, Carmosino I, Bisegna ML, et al
    Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study.
    Br J Haematol. 2026;208:1669-1678.
    >> Share

  44. MCILROY G, Carpenter B, Hough R, James B, et al
    Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.
    Br J Haematol. 2026;208:1745-1757.
    >> Share

  45. CLAUDIANI S, Metelli S, Khan A, Hannah G, et al
    Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.
    Br J Haematol. 2026;208:1660-1668.
    >> Share

  46. YAMAMOTO C, Yamaguchi T, Honda S, Tominaga R, et al
    Cost-effectiveness of blinatumomab as post-remission therapy in adults with measurable residual disease-negative, Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2026;208:1679-1691.
    >> Share

  47. GROLL AH, Cesaro S, Alten J, Attarbaschi A, et al
    Invasive yeast infection in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.
    Br J Haematol. 2026;208:1846-1849.
    >> Share

  48. KIM DH, Park SY, Cho H, Byun JM, et al
    Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.
    Br J Haematol. 2026;208:1724-1733.
    >> Share

    April 2026
  49. VALCARCEL B, Utsunomiya A, Otsuka M, Miyahara M, et al
    Distribution of adult T-cell leukaemia/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study.
    Br J Haematol. 2026 Apr 15. doi: 10.1111/bjh.70494.
    >> Share

  50. JEBARAJ BMC, Stilgenbauer S
    Short and complex-Telomeres and genomes in CLL.
    Br J Haematol. 2026;208:1503-1504.
    >> Share

  51. DESAI N, Althobaiti M, Chen C, Al-Shaibani E, et al
    Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.
    Br J Haematol. 2026;208:1359-1368.
    >> Share

  52. ERIKSEN JVN, de Pietri S, Rathe M, Hasle H, et al
    Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment.
    Br J Haematol. 2026;208:1339-1346.
    >> Share

  53. TIAN Z, Deng Z, Han F, Yu L, et al
    An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL/SLL.
    Br J Haematol. 2026;208:1287-1295.
    >> Share

  54. KOMORI T, Kawai T, Okuno Y, Tsujimoto S, et al
    Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial (JCCG AML-12).
    Br J Haematol. 2026;208:1252-1262.
    >> Share

  55. BIDET A, Laharanne E, Dos Santos M, De Grande AC, et al
    Optical genome mapping detects cryptic high-risk and targetable abnormalities in adult AML.
    Br J Haematol. 2026;208:1232-1239.
    >> Share

  56. MONAGHAN L, Bunschoten RP, Bittencourt-Silvestre J, Park T, et al
    Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia.
    Br J Haematol. 2026;208:1240-1251.
    >> Share

  57. LEE YW, Chiang CJ, Lin YC, Tzeng HE, et al
    Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study.
    Br J Haematol. 2026;208:1278-1286.
    >> Share

  58. DAI X, Wu Z, Zhang W, Chen S, et al
    DHCR7 drives AML development through the IL6/JAK2/STAT3 signalling pathway.
    Br J Haematol. 2026;208:1263-1277.
    >> Share

  59. CRESPO-GARCIA E, Quero-Dotor C, Noguera-Castells A, Sancho-Vila L, et al
    Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia.
    Br J Haematol. 2026;208:1437-1442.
    >> Share

    March 2026
  60. MACPHAIL A, Loke J, Houston BL, Dendle C, et al
    Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice.
    Br J Haematol. 2026;208:981-991.
    >> Share

  61. FLEISCHMANN M, Hansen O, Voigtlander D, Bechwar J, et al
    Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.
    Br J Haematol. 2026;208:905-915.
    >> Share

  62. VERBEEK MWC, Sanders MA, Grashof DGB, Hoogenboezem RM, et al
    The impact of scaRNA12 deregulation on p53-mediated cellular stress response in B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2026;208:883-896.
    >> Share

  63. BRECCIA M, Giai V, Rosso T, Pregno P, et al
    Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study.
    Br J Haematol. 2026;208:974-980.
    >> Share

  64. BOUDRY A, Chevillon F, Marceau-Renaut A, Braun T, et al
    Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.
    Br J Haematol. 2026;208:897-904.
    >> Share

  65. GU J, Wang J, Liu L, Zhang Y, et al
    Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2026;208:954-964.
    >> Share

    February 2026
  66. YEUNG DT, Grigg AP, Reynolds J, Branford S, et al
    The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-alpha2b in newly diagnosed chronic phase chronic myeloid leukaemia.
    Br J Haematol. 2026;208:599-607.
    >> Share

  67. JIN H, Guo Z, Zhu L, Huang F, et al
    Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis.
    Br J Haematol. 2026;208:524-533.
    >> Share

  68. PETERS DT, Nicolet D, Madanat YF, Gonzalez-Lugo J, et al
    Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.
    Br J Haematol. 2026;208:589-598.
    >> Share

  69. WANG LY, Gao HT, Fu Q, Jiang Q, et al
    Decoding the molecular drivers of TP53-mutant acute myeloid leukaemia: Clinical implications and prognostic insights.
    Br J Haematol. 2026;208:579-588.
    >> Share

  70. KYNNING MK, Westerberg E, Forsell L, Creignou M, et al
    Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia-A population-based study.
    Br J Haematol. 2026;208:514-523.
    >> Share

  71. YAO CY, Hsu CL, Yang YT, Tien FM, et al
    Genomic and transcriptomic characterization of acute myeloid leukaemia with IL3RA overexpression: Prognostic and therapeutic implications revisited.
    Br J Haematol. 2026;208:503-513.
    >> Share

  72. LEE BJ, Griffin SP, Doh J, Quach A, et al
    Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia.
    Br J Haematol. 2026;208:570-578.
    >> Share

  73. LIST J, Sollier E, Brown-Burke F, Kelly K, et al
    Genocopy of EVI1-AML with paraneoplastic diabetes insipidus: PRDM16 overexpression by t(1;2)(p36;p21) and enhancer hijacking.
    Br J Haematol. 2026;208:498-502.
    >> Share

  74. KRISTENSEN DT, Simonsen MR, Roug AS, Marcher CW, et al
    Outcomes among non-Western immigrant patients and Danish-born patients with acute myeloid Leukaemia: A Danish population-based cohort study.
    Br J Haematol. 2026;208:564-569.
    >> Share

    January 2026
  75. YI S, Cao J, Feng R, Zhou K, et al
    A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321.
    Br J Haematol. 2026 Jan 22. doi: 10.1111/bjh.70334.
    >> Share

  76. UENO T, Yoshimitsu M, Sameshima M, Nagano T, et al
    Clinical features and incidence of central nervous system involvement in patients with adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2026 Jan 5. doi: 10.1111/bjh.70301.
    >> Share

  77. TAN Y, Zhao X, Suo X, Bai G, et al
    Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study.
    Br J Haematol. 2026;208:189-199.
    >> Share

  78. XU Q, Wang L, Hu S, Liao N, et al
    Risk factors for DIC in paediatric APL: Insights from the CCLG-APL 2016 study.
    Br J Haematol. 2026;208:200-209.
    >> Share

  79. DUPONT M, Derouault P, Pascal V, Dmytruk N, et al
    CLL-like stereotyped BCRs are equally produced in young and old healthy adults, share features of public clonotypes and may be stuck at a pre-germinal centre stage.
    Br J Haematol. 2026;208:106-115.
    >> Share

  80. WU LX, Liao MY, Zhao MY, Yan N, et al
    Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia.
    Br J Haematol. 2026;208:170-178.
    >> Share

  81. HERMANS SJF, Versluis J, van Werkhoven ED, van Norden Y, et al
    Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients.
    Br J Haematol. 2026;208:179-188.
    >> Share

  82. SHANMUGANATHAN N, Grigg A
    A critical review of management of allogeneic transplant-eligible adults with Ph+ acute lymphoblastic leukaemia.
    Br J Haematol. 2026;208:39-53.
    >> Share

    December 2025
  83. KIRK A, James B, Feltbower RG, Mushtaq T, et al
    Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British OsteoNecrosis Study (BONES).
    Br J Haematol. 2025 Dec 18. doi: 10.1111/bjh.70286.
    >> Share

  84. TEFFERI A, Patnaik MM
    Chronic myelomonocytic leukaemia.
    Br J Haematol. 2025;207:2280-2282.
    >> Share

  85. NISCOLA P
    Peripheral blood profiling of azacitidine's hypomethylation: Advancing precision medicine in juvenile chronic myelomonocytic leukaemia.
    Br J Haematol. 2025;207:2661-2662.
    >> Share

  86. CHEN EY, Dickman PW, Di Mari F, Dahlen T, et al
    Empirical and projected economic burden of chronic myeloid leukaemia in Sweden from 2015 to 2030: A population-based study.
    Br J Haematol. 2025;207:2441-2450.
    >> Share

  87. BARRETT N, Gruber TA, Miyamura T, Duguid A, et al
    Infant acute lymphoblastic leukaemia-Progress from worldwide clinical efforts.
    Br J Haematol. 2025;207:2246-2260.
    >> Share

  88. BUCHBINDER N, Michel V, Dalissier A, Kleinschmidt K, et al
    Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party.
    Br J Haematol. 2025;207:2496-2506.
    >> Share

  89. LILIENTHAL I, Tao S, Nilsson C, Leonard E, et al
    Addition of hydroxyurea (hydroxycarbamide) enhances the efficacy of fludarabine/cytarabine-based salvage regimens against acute myeloid leukaemia.
    Br J Haematol. 2025;207:2462-2474.
    >> Share

  90. JEN WY, Tang G, Kugler E, Croden J, et al
    MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia.
    Br J Haematol. 2025;207:2451-2461.
    >> Share

  91. QUIST-PAULSEN P, Horvei L, Dalgaard J, Moksnes M, et al
    Improved outcomes in elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol-A prospective study.
    Br J Haematol. 2025;207:2434-2440.
    >> Share

  92. XAGORARI M, Marmarinos A, Doganis D, Nikita M, et al
    NEAT1 lncRNA overexpression results in short-term progression and poor treatment outcome in childhood B-ALL.
    Br J Haematol. 2025;207:2475-2485.
    >> Share

    November 2025
  93. BERTOLI D, Giupponi C, Rossi G, D'Adda M, et al
    ET occurring in NPM1-mutated AML during molecular complete remission: A further potential evolution of a complex disease.
    Br J Haematol. 2025;207:2153-2157.
    >> Share

  94. METZLER M, Branford S, Hijiya N, Sakamoto K, et al
    An old leukaemia in young patients-Genetic characteristics of paediatric chronic myeloid leukaemia.
    Br J Haematol. 2025;207:1782-1788.
    >> Share

  95. HILLS RK
    Seeing something new or with new eyes?
    Br J Haematol. 2025;207:2231-2232.
    >> Share

  96. DAM M, Centanni M, Centanni D, Friberg LE, et al
    Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study.
    Br J Haematol. 2025;207:1920-1929.
    >> Share

  97. BOUDRY A, Goursaud L, Lebon D, Dumezy F, et al
    Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia.
    Br J Haematol. 2025;207:1953-1961.
    >> Share

  98. YING S, Yang L, Zhang L, Hong R, et al
    The role of CBFbeta::MYH11 fusion gene in acute lysis pneumopathy: A dual impact on risk and prognosis.
    Br J Haematol. 2025;207:1944-1952.
    >> Share

  99. MEYER JA, Xirenayi S, Werner J, Turakulov R, et al
    Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.
    Br J Haematol. 2025;207:1938-1943.
    >> Share

  100. TAMAI M, Komatsu C, Kagami K, Kasai S, et al
    A characteristic gene expression profile regulated by ACIN1::NUTM1 fusion in a newly identified infant leukaemic cell line and an ACIN1::NUTM1-inducible model.
    Br J Haematol. 2025;207:1842-1854.
    >> Share

  101. HOANG T, Cheung MC, Juurlink DN, Chan KKW, et al
    Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2025;207:1893-1901.
    >> Share

  102. SHIMONI A, Peczynski C, Labopin M, Dominietto A, et al
    Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working
    Br J Haematol. 2025;207:2041-2048.
    >> Share

  103. ROKKANEN R, Aarnivala H, Huhtaniska S, Palmu S, et al
    Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.
    Br J Haematol. 2025;207:1912-1919.
    >> Share

    October 2025
  104. SHICHIJO T, Tatetsu H, Higuchi Y, Miyakawa T, et al
    Prognostic impact of valemetostat in relapsed/refractory adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2025 Oct 23. doi: 10.1111/bjh.70219.
    >> Share

  105. ZHANG X, Wang L, Kuang N, Yang J, et al
    Immune reconstitution after CD7 CAR-T cell therapy for refractory/relapsed acute T-lymphoblastic leukaemia/lymphoblastic lymphoma (R/R T-ALL/LBL).
    Br J Haematol. 2025 Oct 19. doi: 10.1111/bjh.70201.
    >> Share

  106. POURHASSAN H, Tinajero J, Ma H, Jackson R, et al
    The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia.
    Br J Haematol. 2025;207:1377-1387.
    >> Share

  107. NACHMIAS B, Haran A, Yisraeli Salman M, Stein EM, et al
    Measurable residual disease-guided therapy in acute myeloid leukaemia: Practical insights.
    Br J Haematol. 2025;207:1192-1212.
    >> Share

  108. SHARMA P, Leons GK, Singh V, Naseer S, et al
    Gene expression signature of IKZF1 deleted B-cell acute lymphoblastic leukaemia reveals a unique regulation of MUC4.
    Br J Haematol. 2025;207:1259-1270.
    >> Share

  109. LIANG H, He B, Chen J, Luo B, et al
    Paediatric-inspired regimen reduces central nervous system relapse in adult acute lymphoblastic leukaemia.
    Br J Haematol. 2025;207:1445-1453.
    >> Share

  110. EGGER-HEIDRICH K, Sockel K, Schetelig J
    Back to life: Biological parenthood of young adult acute leukaemia survivors.
    Br J Haematol. 2025;207:1728-1730.
    >> Share

  111. HERLIN MK, Kjeldsen E, Abrahamsson J, Arad-Cohen N, et al
    Characteristics and prognosis of paediatric normal karyotype acute myeloid leukaemia: A NOPHO-DBH AML study.
    Br J Haematol. 2025;207:1454-1463.
    >> Share

  112. SHI H, Shu W, Tao Y, Jia X, et al
    White blood cell count as a powerful prognostic marker and treatment guide in paediatric acute myeloid leukaemia with NUP98 rearrangement.
    Br J Haematol. 2025;207:1464-1475.
    >> Share

  113. YUAN M, Zhang Y, Liu B, Zhou L, et al
    Treatment-free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure.
    Br J Haematol. 2025;207:1408-1415.
    >> Share

  114. LIU Y, Liu W, Mei Y, Huang Q, et al
    Single-cell transcriptome profiling reveals blast cell heterogeneity and identifies novel therapeutic target IKZF2 in t(8;21) acute myeloid leukaemia.
    Br J Haematol. 2025;207:1309-1322.
    >> Share

  115. ZHONG M, Yin C, Wang Y, Zeng L, et al
    HOX11 gene overexpression is associated with recurrence of acute B lymphoblastic leukaemia.
    Br J Haematol. 2025;207:1301-1308.
    >> Share

  116. HUANG N, Chang C, Wu L, He Q, et al
    Characteristics and prognostic implications of TP53 mutations in Chinese patients with myelodysplastic syndromes.
    Br J Haematol. 2025;207:1397-1407.
    >> Share

  117. MUNYURANGABO G, Zhang L, Zhou Y, Zhang P, et al
    Co-operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity.
    Br J Haematol. 2025;207:1289-1300.
    >> Share

  118. SKOPEK R, Ozcan SG, Chmiel P, Morgner S, et al
    Synergistic potential of CDK4/6 inhibitors and ATRA in non-APL AML.
    Br J Haematol. 2025;207:1279-1288.
    >> Share

  119. DANYLESKO I, Shimoni A, Avigdor A, Kedmi M, et al
    Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I/II study.
    Br J Haematol. 2025;207:1425-1434.
    >> Share

  120. SCHONUNG M, Rathmann S, Ramamoorthy S, Lebrecht D, et al
    Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG-MESRAT study.
    Br J Haematol. 2025;207:1271-1278.
    >> Share

  121. ANGOTZI F, Cellini A, Danesin N, Zoletto S, et al
    Serum soluble interleukin-2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring.
    Br J Haematol. 2025;207:1357-1365.
    >> Share

  122. DREYZIN A, Holtzman NG, Bonifant CL
    CD123-targeting immunotherapeutic approaches in acute myeloid leukaemia.
    Br J Haematol. 2025;207:1178-1191.
    >> Share

  123. JENSEN RH, Teglgaard C, Jensen JF, Baech J, et al
    Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline-containing chemotherapy: A population-based matched cohort study.
    Br J Haematol. 2025;207:1416-1424.
    >> Share

  124. NIELSEN NN, Jensen JF, Ovlisen A, Zenas DR, et al
    Reproductive patterns and birth rates in acute leukaemia survivors: A Danish population-based cohort study.
    Br J Haematol. 2025;207:1435-1444.
    >> Share

    September 2025
  125. LI Y, Jin L, Liu W, Liu Y, et al
    Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma.
    Br J Haematol. 2025 Sep 16. doi: 10.1111/bjh.70097.
    >> Share

  126. LI X, Zhou Q, Hao X, Cao C, et al
    Targeting NLRP1-CCL8 axis in the leukaemic niche suppresses AML via inhibition of PI3K-AKT signalling.
    Br J Haematol. 2025;207:789-801.
    >> Share

  127. CHENG CN, Yang YN, Yeh YH, Chen JS, et al
    The impact of secondary hypogammaglobulinaemia in children with acute lymphoblastic leukaemia receiving maintenance chemotherapy.
    Br J Haematol. 2025;207:892-901.
    >> Share

  128. KOSYDAR S, Archibald WJ, Hampel PJ, Call TG, et al
    The role of imaging studies in predicting time to first treatment and overall survival in high-count monoclonal B-cell lymphocytosis.
    Br J Haematol. 2025;207:860-868.
    >> Share

  129. ZU Y, Yue X, Zhan X, Liu X, et al
    Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes.
    Br J Haematol. 2025;207:834-841.
    >> Share

  130. ROLLES B, Chatain N, Gorg R, Vieri M, et al
    ZIP10 as a potential therapeutic target in acute myeloid leukaemia.
    Br J Haematol. 2025;207:767-779.
    >> Share

    August 2025
  131. YU F, Yu X, Hu X, Jiang E, et al
    Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025 Aug 26. doi: 10.1111/bjh.70102.
    >> Share

  132. TE VRUGT M, Newman H, Teachey DT, Burkhardt B, et al
    T-cell lymphoblastic lymphoma in children, adolescents and young adults.
    Br J Haematol. 2025 Aug 13. doi: 10.1111/bjh.70053.
    >> Share

  133. TINAJERO J, Ngo D, Motta M, Agrawal V, et al
    The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission.
    Br J Haematol. 2025;207:426-431.
    >> Share

  134. BORJA-MONTES OF, Toro-Pedroza A, Epperla N, Andritsos LA, et al
    Hairy cell leukaemia and pregnancy: A systematic review and review of literature.
    Br J Haematol. 2025;207:678-682.
    >> Share

  135. NACHTKAMP K, Schulz F, Gattermann N, Germing U, et al
    Clinical management of CMML-State of the art.
    Br J Haematol. 2025;207:350-364.
    >> Share

  136. SAVONA MR, Odenike O, Roboz GJ, Amin H, et al
    Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.
    Br J Haematol. 2025;207:432-444.
    >> Share

  137. KONUMA T, Shimomura Y, Mizuno S, Yamasaki S, et al
    Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantat
    Br J Haematol. 2025;207:484-497.
    >> Share

  138. XIAO J, Xia Y, Yin F, Shi Z, et al
    Global spatiotemporal distribution characteristics and regional risk stratification model of acute myeloid leukaemia based on molecular genetics and cytogenetic features.
    Br J Haematol. 2025;207:395-406.
    >> Share

    July 2025
  139. YE Y, Liu X, Dai H, Hu J, et al
    Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study.
    Br J Haematol. 2025;207:151-161.
    >> Share

  140. WANG M, Guo Z, Zhao S, Liu L, et al
    CD49d promotes T-cell senescence in chronic lymphocytic leukaemia.
    Br J Haematol. 2025;207:80-91.
    >> Share

  141. WILKE AC, Gokbuget N
    The role of blinatumomab in adult acute B lymphoblastic leukaemia.
    Br J Haematol. 2025;207:27-42.
    >> Share

  142. LIN ME, Hsu YC, Chiu HL, Yao CY, et al
    Inhibition of DOCK1 suppresses Notch signalling pathway and impairs leukaemogenesis.
    Br J Haematol. 2025;207:59-68.
    >> Share

  143. BEHRENS YL, Reinkens T, Hofmann W, Gumann A, et al
    Genomic variant profiling in blast-phase paediatric chronic myeloid leukaemia: Predisposing and driving alterations.
    Br J Haematol. 2025;207:141-150.
    >> Share

  144. LUO Y, Fu Y, Kuang M, Wang J, et al
    Ciclosporin A potentiates venetoclax efficacy in FLT3-ITD AML by targeting the NFATC1-AKT-mTOR-BCL-2/MCL-1 signaling axis.
    Br J Haematol. 2025;207:46-58.
    >> Share

    June 2025
  145. AGRAWAL V, Arslan S, Pourhassan H, Koller P, et al
    Hypomethylating agent and venetoclax are effective salvage therapies in relapsed/refractory early T-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2025;206:1678-1682.
    >> Share

  146. HEIBLIG M, Plesa A, Tantot J, Jamilloux Y, et al
    Myeloid neoplasm inspired intensive therapy in VEXAS syndrome: A single-centre experience.
    Br J Haematol. 2025;206:1683-1688.
    >> Share

  147. HUANG YJ, Liu HC, Kuo MC, Yeh TC, et al
    Frequency and prognostic value of unconventional genetic subtypes in paediatric and young adult B-cell precursor acute lymphoblastic leukaemia in Taiwan.
    Br J Haematol. 2025;206:1699-1709.
    >> Share

    May 2025
  148. AOKI T, Salib M, Suleman A, Ghanem N, et al
    Distinct characteristics and social determinants in adult T-cell leukaemia/lymphoma patients at a tertiary cancer centre in Canada.
    Br J Haematol. 2025 May 6. doi: 10.1111/bjh.20132.
    >> Share

  149. SCARADAVOU A
    Cord blood transplants: Advancing leukaemia treatments and addressing health disparities.
    Br J Haematol. 2025;206:1312-1314.
    >> Share

  150. ZHENG Z, Wang W, Feng M, Chen X, et al
    The mechanism of EZH2/H3K27me3 downregulating CXCL10 to affect CD8(+) T cell exhaustion to participate in the transformation from myelodysplastic syndrome to acute myeloid leukaemia.
    Br J Haematol. 2025;206:1335-1349.
    >> Share

  151. VICENTE-GARCES C, Fernandez G, Esperanza-Cebollada E, Richarte-Franques M, et al
    RNA-sequencing: A reliable tool to unveil transcriptional landscape of paediatric B-other acute lymphoblastic leukaemia.
    Br J Haematol. 2025;206:1355-1365.
    >> Share

  152. LIU J, Zhao XS, Chang YJ, Qin YZ, et al
    Monitoring the KMT2A gene post-chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025;206:1418-1429.
    >> Share

  153. SUTTORP M, Sembill S, Lensker P, Hildebrand V, et al
    Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting.
    Br J Haematol. 2025;206:1397-1405.
    >> Share

  154. STASIK S, Eckardt JN, Rollig C, Baldus CD, et al
    The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML.
    Br J Haematol. 2025;206:1373-1379.
    >> Share

    April 2025
  155. ZHAO C, Xiao MY, Zhang F, Bai L, et al
    Outcomes and prognostic factors associated with relapse after haploidentical stem cell transplantation for paediatric T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2025;206:1165-1172.
    >> Share

  156. CONNERTY P, Xie J, El-Najjar F, Trahair TN, et al
    Immune-deficient MISTRG mice support expansion of leukaemia-initiating cells in xenograft models of paediatric acute myeloid leukaemia.
    Br J Haematol. 2025;206:1092-1096.
    >> Share

  157. PRATZ KW
    Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1.
    Br J Haematol. 2025;206:1250-1252.
    >> Share

  158. FRERICH C, Li P, Raess PW, Dunlap J, et al
    Landscape of somatic mutations and clonal evolution in NUP98-rearranged adult acute myeloid leukaemia.
    Br J Haematol. 2025;206:1097-1102.
    >> Share

  159. DE BOTTON S, Recher C, Cortes J, Curti A, et al
    Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.
    Br J Haematol. 2025;206:1121-1128.
    >> Share

    March 2025
  160. PERUTELLI F, Boccellato E, Montalbano MC, Catania G, et al
    Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025;206:924-929.
    >> Share

  161. SERAFIN A, Ruocco V, Cellini A, Angotzi F, et al
    Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype.
    Br J Haematol. 2025;206:832-841.
    >> Share

  162. VALTIS YK, Luskin MR
    Better late than never: Delayed asparaginase during induction for acute lymphoblastic leukaemia in adults.
    Br J Haematol. 2025;206:1016-1017.
    >> Share

  163. LAING A, Elmarghany A, Alghaith AA, Gouma A, et al
    Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact-independent mechanism.
    Br J Haematol. 2025;206:858-863.
    >> Share

  164. TINAJERO J, Xu S, Ngo D, Li S, et al
    Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes.
    Br J Haematol. 2025;206:868-875.
    >> Share

    February 2025
  165. ZHAO J, Liu TF, Wu KF, Yang LC, et al
    Clinical and molecular characteristics of paediatric mature B-cell acute lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups.
    Br J Haematol. 2025 Feb 17. doi: 10.1111/bjh.20011.
    >> Share

  166. CHEN Z, Ren A, Li Y, Shu J, et al
    mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells.
    Br J Haematol. 2025;206:628-643.
    >> Share

  167. LIN CC, Hsu CL, Yao CY, Wang YH, et al
    HOPX as a tumour-suppressive protein in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2025;206:505-516.
    >> Share

  168. GANZEL C, Frisch A, Wolach O, Moshe Y, et al
    CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.
    Br J Haematol. 2025;206:551-555.
    >> Share

  169. GURNARI C, Visconte V
    Dissecting the genomic traits and clinical course of secondary myelodysplastic syndrome following aplastic anaemia: A milestone.
    Br J Haematol. 2025;206:790-791.
    >> Share

  170. ESTELLER M
    Targeting RNA modifications in leukaemia: Epitranscriptomic drugs are the new kids on the block.
    Br J Haematol. 2025;206:785-787.
    >> Share

  171. CHEN X, Gong RZ, Mo LY, Cheng YT, et al
    Hydroxy-wybutosine tRNA modifications as indicators of disease progression and therapeutic targets in leukaemia.
    Br J Haematol. 2025;206:517-530.
    >> Share

    January 2025
  172. SWEET K, Cluzeau T
    Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025;206:61-68.
    >> Share

  173. COSTA A, Scalzulli E, Breccia M
    Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategies.
    Br J Haematol. 2025;206:44-60.
    >> Share

  174. HA TQ, Andresen V, Erikstein BS, Popa M, et al
    Preclinical activity of resazurin in acute myeloid leukaemia.
    Br J Haematol. 2025;206:109-119.
    >> Share

  175. JIANG L, Cheng J, Sun J, Zhang Y, et al
    Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia-related mutations in first remission.
    Br J Haematol. 2025;206:250-262.
    >> Share

  176. VEDI A, Leiter SM, Memon IL, Mahendrayogam A, et al
    Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland.
    Br J Haematol. 2025;206:204-208.
    >> Share

  177. DAVIDS MS, Lin KH, Mohamed AI, Munir T, et al
    Measurable residual disease-driven treatment in first-line chronic lymphocytic leukaemia.
    Br J Haematol. 2025;206:33-43.
    >> Share

  178. TRKA J, Fronkova E
    Minimal residual disease detection for acute lymphoblastic leukaemia in peripheral blood-Are we there yet?
    Br J Haematol. 2025;206:397-398.
    >> Share

  179. HUANG Q, Jiang X, Wang B, Wu Z, et al
    Gallic acid enhances GVL effects of T cells without exacerbating GVHD after haematopoietic stem cell transplantation.
    Br J Haematol. 2025;206:120-132.
    >> Share

  180. THERON A, Alonso-Saladrigues A, Dapena JL, Lopez-Duarte M, et al
    Secondary haematological dysplasia after CAR-T-cell therapy for acute lymphoblastic leukaemia in children.
    Br J Haematol. 2025;206:186-194.
    >> Share

  181. COUSSON S, Calvo C, Goldwirt L, Simonin M, et al
    Monocentric experience of venetoclax-based regimen in paediatric refractory and relapsed AML/MDS.
    Br J Haematol. 2025;206:209-214.
    >> Share

    December 2024
  182. FROST EL, Chonat S, Williams KM, Aumann W, et al
    Fatal thrombotic microangiopathy during induction for acute myeloid leukemia: A case report and review of vascular complications in germline GATA2 haploinsufficiency.
    Br J Haematol. 2024 Dec 8. doi: 10.1111/bjh.19935.
    >> Share

  183. HUGUET F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, et al
    Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.
    Br J Haematol. 2024;205:2295-2304.
    >> Share

  184. MORIGUCHI M, Nakamae H, Nishimoto M, Sugita J, et al
    Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia.
    Br J Haematol. 2024;205:2376-2386.
    >> Share

  185. KONDO T
    A new face in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:2131-2133.
    >> Share

  186. PULA AE, Robak T
    The discovery of the RCC1::IRF4 Fusion in CLL patients with t(1;6)(p35.3;p25.2) chromosomal translocation.
    Br J Haematol. 2024;205:2125-2127.
    >> Share

  187. BOUSSI L, Biswas J, Abdel-Wahab O, Stein E, et al
    Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.
    Br J Haematol. 2024;205:2153-2162.
    >> Share

  188. JAYNE S, Lopez C, Put N, Nagel I, et al
    The chromosomal translocation t(1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1::IRF4 fusion.
    Br J Haematol. 2024;205:2321-2326.
    >> Share

  189. TERUEL-MONTOYA R, Rivera J, Lozano ML
    The importance of genetic variant cleaners: From patient to wet lab and back to clinical practice.
    Br J Haematol. 2024;205:2122-2124.
    >> Share

  190. KAMIYA LJ, Barozzi S, Isidori F, Ganiewich D, et al
    Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis.
    Br J Haematol. 2024;205:2315-2320.
    >> Share

  191. LIU W, Wang C, Ouyang W, Hao J, et al
    Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed/refractory disease.
    Br J Haematol. 2024;205:2228-2233.
    >> Share

  192. ASHOURI K, Hom B, Ginosyan AA, Rahimi Y, et al
    Philadelphia-like B-cell acute lymphoblastic leukaemia: Disease features and outcomes in the era of immunotherapy.
    Br J Haematol. 2024;205:2234-2247.
    >> Share

    November 2024
  193. LV M, Yan CH, Ma R, He Y, et al
    Mega-dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study.
    Br J Haematol. 2024;205:1910-1920.
    >> Share

  194. BOULIGNY IM, DiNardo CD
    Oral decitabine-cedazuridine in acute myeloid leukaemia.
    Br J Haematol. 2024;205:1674-1676.
    >> Share

  195. GEISSLER K, Koristek Z, Del Castillo TB, Novak J, et al
    Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.
    Br J Haematol. 2024;205:1734-1745.
    >> Share

  196. PHILIP C, Selvarajan S, Nayak L, Jain H, et al
    Impact of the COVID-19 pandemic on treatment of patients with acute myeloid leukaemia in India.
    Br J Haematol. 2024;205:2058-2062.
    >> Share

  197. YANADA M
    Leucocytosis during all-trans retinoic acid and arsenic trioxide treatment in acute promyelocytic leukaemia.
    Br J Haematol. 2024;205:1672-1673.
    >> Share

  198. MAILLET F, Galimard JE, Borie R, Lainey E, et al
    Haematological features of telomere biology disorders diagnosed in adulthood: A French nationwide study of 127 patients.
    Br J Haematol. 2024;205:1835-1847.
    >> Share

  199. ARIFFIN H
    Incorrigible inflammation.
    Br J Haematol. 2024;205:1679-1680.
    >> Share

  200. CICCONI L, Bisegna M, Gurnari C, Fanciullo D, et al
    Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications.
    Br J Haematol. 2024;205:1727-1733.
    >> Share

  201. SPECTOR LG, de Smith AJ
    Backtracking childhood leukaemia to birth: A battle of addition.
    Br J Haematol. 2024;205:1670-1671.
    >> Share

  202. YANG YT, Yao CY, Kao CJ, Chiu PJ, et al
    Clinical relevance of NFYA splice variants in patients with acute myeloid leukaemia undergoing intensive chemotherapy.
    Br J Haematol. 2024;205:1751-1764.
    >> Share

  203. XU N, Dao FT, Shi ZY, Sun K, et al
    WT1 together with RUNX1::RUNX1T1 targets DUSP6 to dampen ERK activity in acute myeloid leukaemia.
    Br J Haematol. 2024;205:1848-1859.
    >> Share

  204. ZHU Q, Nambiar R, Schultz E, Gao X, et al
    Genome-wide study identifies novel genes associated with bone toxicities in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:1889-1898.
    >> Share

  205. BARDINI M, Fazio G, Abascal LC, Meyer C, et al
    Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:1883-1888.
    >> Share

  206. WEINBERGEROVA B, Mayer J, Kabut T, Sperr WR, et al
    Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.
    Br J Haematol. 2024;205:1746-1750.
    >> Share

    October 2024
  207. YOSHIMITSU M, Tanaka T, Nakano N, Kato K, et al
    Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2024 Oct 19. doi: 10.1111/bjh.19835.
    >> Share

  208. NAKAMURA M, Chonabayashi K, Narita M, Matsumura Y, et al
    Modelling and drug targeting of a myeloid neoplasm with atypical 3q26/MECOM rearrangement using patient-specific iPSCs.
    Br J Haematol. 2024;205:1430-1443.
    >> Share

  209. GHOSH N, Manzoor BS, Fakhri B, Emechebe N, et al
    Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.
    Br J Haematol. 2024;205:1395-1403.
    >> Share

  210. GAO MY, Georgiou A, Lin VS, Jahja M, et al
    Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implications.
    Br J Haematol. 2024;205:1389-1394.
    >> Share

  211. MEHTA P, Campbell V, Maddox J, Floisand Y, et al
    CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.
    Br J Haematol. 2024;205:1326-1336.
    >> Share

  212. ANASTASOPOULOU S, Swann G, Andres-Jensen L, Attarbaschi A, et al
    Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group Study.
    Br J Haematol. 2024;205:1450-1459.
    >> Share

    September 2024
  213. NARESH KN
    Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli: Diagnosis, underpinnings for disease classification and future directions.
    Br J Haematol. 2024 Sep 10. doi: 10.1111/bjh.19754.
    >> Share

  214. HEI Z, Yang S, Ouyang G, Hanna J, et al
    Targeting the redox vulnerability of acute myeloid leukaemia cells with a combination of auranofin and vitamin C.
    Br J Haematol. 2024;205:1017-1030.
    >> Share

  215. LEBLANC FR, Breese EH, Burns KC, Chang EK, et al
    Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.
    Br J Haematol. 2024;205:1055-1066.
    >> Share

  216. HUANG C, Jia Y, Yang J, Cai Y, et al
    Azacitidine combined with interferon-alpha for pre-emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study.
    Br J Haematol. 2024;205:1067-1076.
    >> Share

  217. GOVER-PROAKTOR A, Leshem-Lev D, Winograd-Katz S, Partouche S, et al
    Dasatinib induces endothelial dysfunction leading to impaired recovery from ischaemia.
    Br J Haematol. 2024;205:1011-1016.
    >> Share

  218. KUGLER E, Cohen I, Amitai I, Ram R, et al
    Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;205:932-941.
    >> Share

  219. KUHN MWM, Ganser A
    The Menin story in acute myeloid leukaemia-The road to success.
    Br J Haematol. 2024;205:812-814.
    >> Share

  220. ZHAO S, Wang J, Lou Y, Huang X, et al
    Clinical characteristics of acute myeloid leukaemia patients with a large number of azurophilic granules: A single-centre retrospective study.
    Br J Haematol. 2024;205:924-931.
    >> Share

  221. ROBERTSON HF, Milojkovic D, Butt N, Byrne J, et al
    Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy.
    Br J Haematol. 2024;205:947-955.
    >> Share

  222. MARCHAND T, Pastoret C, Damaj G, Lebouvier A, et al
    Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia.
    Br J Haematol. 2024;205:915-923.
    >> Share

    August 2024
  223. GLANZMANN J, Kalberer C, Bonadies N, Colucci G, et al
    Plasma cells with Auer-rod-like inclusions in a patient with MGUS and acute myeloid leukaemia with NPM1 mutation.
    Br J Haematol. 2024;205:401-402.
    >> Share

  224. YANG F, Ren Q, Zu Y, Gui R, et al
    Multiple small-dose infusions of G-CSF-mobilized haploidentical lymphocytes after autologous haematopoietic stem cell transplantation for acute myeloid leukaemia.
    Br J Haematol. 2024;205:645-652.
    >> Share

  225. TRINQUAND A, Betts DR, Rooney S, Storey L, et al
    MRD-risk stratification mitigates TLX3 prognostic impact in paediatric T-cell acute lymphoblastic leukaemia: A national cohort analysis.
    Br J Haematol. 2024;205:729-732.
    >> Share

  226. CHEN C, Li J, Chen Y, Gao Q, et al
    The correlation of asparaginase enzyme activity levels after PEG-asparaginase administration with clinical characteristics and adverse effects in Chinese paediatric patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:624-633.
    >> Share

  227. ZHU W, Ding Y, Huang W, Guo N, et al
    Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI-503 against MLL::AF9-driven acute myeloid leukaemia.
    Br J Haematol. 2024;205:568-579.
    >> Share

  228. GRADY E, Biswas S, Dias T, McCarthy P, et al
    A novel TCF3::PIK3R1 fusion linked to decreased PI3K-AKT signalling activity in paediatric B-acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:738-741.
    >> Share

  229. OTHMAN T, Koller P, Pourhassan H, Agrawal V, et al
    Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:711-715.
    >> Share

  230. WANG S, Liu Y, Zhao X, Wang X, et al
    RUNX1::ETO and CBFbeta::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core-binding factor-acute myeloid leukaemia.
    Br J Haematol. 2024;205:552-567.
    >> Share

  231. TANG FF, Duan WB, Liu XH, Lu SY, et al
    A complete oral regimen for induction therapy of patients with high-risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy.
    Br J Haematol. 2024;205:510-516.
    >> Share

  232. NGUYEN-KHAC F, Baron M, Guieze R, Feugier P, et al
    Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
    Br J Haematol. 2024;205:495-502.
    >> Share

  233. XU X, Huang Z, Ding C, Deng S, et al
    STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:517-528.
    >> Share

  234. BOTTEN GA, Zhang Y, Fuda F, Koduru P, et al
    T/myeloid mixed phenotype acute leukaemia harbouring TLX3::BCL11B with TLX3 activation.
    Br J Haematol. 2024;205:607-612.
    >> Share

    July 2024
  235. ALLEN B, Savoy L, Ryabinin P, Bottomly D, et al
    Upregulation of HOXA3 by isoform-specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemia.
    Br J Haematol. 2024;205:207-219.
    >> Share

  236. RONNACKER J, Urbahn MA, Reicherts C, Kolloch L, et al
    Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia.
    Br J Haematol. 2024;205:280-290.
    >> Share

  237. JIMENEZ-VICENTE C, Charry P, Castano-Diez S, Guijarro F, et al
    Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.
    Br J Haematol. 2024;205:256-267.
    >> Share

  238. PICHLER H, Sedlacek P, Meisel R, Beier R, et al
    Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group.
    Br J Haematol. 2024;205:268-279.
    >> Share

  239. TAURINO G, Dander E, Chiu M, Pozzi G, et al
    Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP-ALL cell survival and a potential therapeutic target.
    Br J Haematol. 2024;205:175-188.
    >> Share

  240. WANG HY, Louis HMS, Costello CL, Murray SS, et al
    A CD10-negative adult B-lymphoblastic leukaemia with amplification of KMT2A without rearrangement: A case report and review of the English literature.
    Br J Haematol. 2024;205:364-367.
    >> Share

  241. DOURTHE ME, Yakouben K, David A, Thouvenin S, et al
    Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:373-377.
    >> Share

  242. JEN WY, Kantarjian H, Kadia TM, DiNardo CD, et al
    Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
    Br J Haematol. 2024;205:30-47.
    >> Share

  243. SERAFIN A, Cellini A, Cavarretta CA, Ruocco V, et al
    Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens.
    Br J Haematol. 2024;205:189-193.
    >> Share

  244. ZHANG X, Zhong Y, Liu L, Suo S, et al
    MN1::ETV6-positive de novo T-cell acute lymphoblastic leukaemia is sensitive to venetoclax: A case report.
    Br J Haematol. 2024;205:352-355.
    >> Share

  245. IYENGAR L, Fong CY, Prakash S, Chong AH, et al
    Cutaneous involvement in chronic lymphocytic leukaemia.
    Br J Haematol. 2024;205:11.
    >> Share

  246. POURHASSAN H, Zhang J, Tinajero J, Pullarkat V, et al
    Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.
    Br J Haematol. 2024;205:158-165.
    >> Share

    June 2024
  247. XU J, Peng J, Sun S, Wang D, et al
    Preclinical testing of CT1113, a novel USP28 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:2301-2318.
    >> Share

  248. DELGADO J
    InsT-ALLing CD7 chimeric antigen receptors before transplantation.
    Br J Haematol. 2024;204:2155-2156.
    >> Share

  249. ENJETI AK, Fogler WE, Smith TAG, Lincz LF, et al
    Combining 5-azacitidine with the E-selectin antagonist uproleselan is an effective strategy to augment responses in myelodysplasia and acute myeloid leukaemia.
    Br J Haematol. 2024;204:2264-2274.
    >> Share

  250. ORTIZ ROJAS CA, Pereira-Martins DA, Bellido More CC, Sternadt D, et al
    A 4-gene prognostic index for enhancing acute myeloid leukaemia survival prediction.
    Br J Haematol. 2024;204:2287-2300.
    >> Share

  251. LIU H, Wu K, Hu W, Chen X, et al
    Immunophenotypic clustering in paediatric acute myeloid leukaemia.
    Br J Haematol. 2024;204:2275-2286.
    >> Share

  252. MAO S, Lin Y, Qin X, Miao Y, et al
    Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML.
    Br J Haematol. 2024;204:2332-2341.
    >> Share

  253. JEN WY, Sasaki K, Loghavi S, Wang SA, et al
    Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
    Br J Haematol. 2024;204:2259-2263.
    >> Share

  254. KINSELLA FAM, Maroto MAL, Loke J, Craddock C, et al
    Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia.
    Br J Haematol. 2024;204:2173-2183.
    >> Share

  255. ROLLIG C, Schliemann C, Ruhnke L, Fransecky L, et al
    Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
    Br J Haematol. 2024;204:2254-2258.
    >> Share

  256. ONIDA F, Gras L, Ge J, Koster L, et al
    Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT.
    Br J Haematol. 2024;204:2365-2377.
    >> Share

  257. HARROP S, Nguyen PC, Robinson S, Nguyen T, et al
    Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications.
    Br J Haematol. 2024;204:2492-2495.
    >> Share

  258. BARNBROCK A, Moricke A, Barbaric D, Jones N, et al
    Pneumocystis jirovecii pneumonia in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.
    Br J Haematol. 2024;204:2319-2323.
    >> Share

  259. DONG Q, Wang Y, Xiu Y, Wu X, et al
    Unveiling myeloid transformation: T-LGLL with eosinophilia masking myeloid-associated STAT5B mutation culminating in AML.
    Br J Haematol. 2024;204:2487-2491.
    >> Share

  260. BAUCH T, Hempel G
    Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:2324-2331.
    >> Share

    May 2024
  261. RUPAKUMAR T, Sankar A, Vijayasekharan K, Varikkattu Rajendran P, et al
    Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic leukaemia/lymphoma: Experience from a tertiary care centre in South India.
    Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19559.
    >> Share

  262. BALDUZZI A
    The CAR T-cell race: The rules of the game.
    Br J Haematol. 2024;204:1579-1581.
    >> Share

  263. ZHANG X, Tao C, Long F
    Haematoidin in chronic myelomonocytic leukaemia during irregular treatment with hydroxycarbamide.
    Br J Haematol. 2024;204:1569-1570.
    >> Share

  264. MISHRA AK, Burridge S, Espuelas MO, O'Reilly M, et al
    Practice guideline: Preparation for CAR T-cell therapy in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1687-1696.
    >> Share

  265. KRIEGER E, Qayyum R, Toor A
    Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.
    Br J Haematol. 2024;204:1935-1943.
    >> Share

  266. LEBECQUE B, Besombes J, Dannus LT, De Antonio M, et al
    Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up.
    Br J Haematol. 2024;204:1872-1881.
    >> Share

  267. JO T, Ueda T, Akahoshi Y, Kondo T, et al
    First complete remission favours haploidentical haematopoietic stem cell transplantation with post-transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1913-1919.
    >> Share

  268. BOUKOUACI W, Rivera-Franco MM, Volt F, Lajnef M, et al
    HLA peptide-binding pocket diversity modulates immunological complications after cord blood transplant in acute leukaemia.
    Br J Haematol. 2024;204:1920-1934.
    >> Share

  269. BRILLEMBOURG H, Martinez-Cibrian N, Bachiller M, Alserawan L, et al
    The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
    Br J Haematol. 2024;204:1649-1659.
    >> Share

  270. LOH Z, Ashby M, Van Veldhuizen E, Li W, et al
    Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.
    Br J Haematol. 2024;204:1732-1739.
    >> Share

    April 2024
  271. HUO W, Gao L, Song K, Huang J, et al
    Allogeneic haematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicentre analysis in China.
    Br J Haematol. 2024 Apr 25. doi: 10.1111/bjh.19481.
    >> Share

  272. CAO XY, Zhang JP, Lu Y, Zhao YL, et al
    A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen r
    Br J Haematol. 2024 Apr 13. doi: 10.1111/bjh.19445.
    >> Share

  273. LIU HC, Huang YJ, Jaing TH, Wu KH, et al
    Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1(plus) and Day 15 MRD positivity.
    Br J Haematol. 2024;204:1344-1353.
    >> Share

  274. BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al
    Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1367-1374.
    >> Share

  275. CHEN X, Li J, Yu L, Hu W, et al
    High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
    Br J Haematol. 2024;204:1354-1366.
    >> Share

  276. MOSQUERA ORGUEIRA A, Perez Encinas MM, Diaz Varela N, Wang YH, et al
    Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
    Br J Haematol. 2024;204:1529-1535.
    >> Share

  277. STENTOFT J
    The Mozart effect in chronic myeloid leukaemia.
    Br J Haematol. 2024;204:1139-1140.
    >> Share

  278. PATEL SA
    The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
    Br J Haematol. 2024;204:1137-1138.
    >> Share

  279. ZHANG T, Zhang Y, Zhou M, Zhang Z, et al
    Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:1402-1413.
    >> Share

  280. ALCAZER V, Morisset S, Rea D, Legros L, et al
    Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
    Br J Haematol. 2024;204:1536-1539.
    >> Share

  281. JOHNSON IM, Karrar O, Rana M, Iftikhar M, et al
    Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
    Br J Haematol. 2024;204:1232-1237.
    >> Share

  282. NACHMIAS B, Aumann S, Haran A, Schimmer AD, et al
    Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights.
    Br J Haematol. 2024;204:1146-1158.
    >> Share

  283. ZUCENKA A, Griskevicius L
    Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;204:1227-1231.
    >> Share

  284. SUWANNAYING K, Ong AA, Dhaduk R, Pei D, et al
    Quantitative computed tomography analysis of body composition changes in paediatric patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1335-1343.
    >> Share

  285. FIEDLER W
    Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy.
    Br J Haematol. 2024;204:1135-1136.
    >> Share

  286. LIANG P, Xie Y, Liu Z, Wang D, et al
    Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia.
    Br J Haematol. 2024;204:1219-1226.
    >> Share

  287. ROY MOULIK N, Keerthivasagam S, Pandey A, Agiwale J, et al
    Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
    Br J Haematol. 2024;204:1249-1261.
    >> Share

  288. MADERO-MARROQUIN R, DuVall AS, Saygin C, Wang P, et al
    Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
    Br J Haematol. 2024;204:1238-1242.
    >> Share

  289. LIGIA S, Passucci M, Assanto GM, D'Elia GM, et al
    Early clearance of hairy cell leukaemia in the bone marrow after first-line treatment with cladribine predicts a favourable outcome.
    Br J Haematol. 2024;204:1288-1292.
    >> Share

    March 2024
  290. LARIBI K, Poulain S, Willems L, Merabet F, et al
    Long-term results of Waldenstrom macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
    Br J Haematol. 2024 Mar 19. doi: 10.1111/bjh.19409.
    >> Share

  291. NG HL, Robinson ME, May PC, Innes AJ, et al
    Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells.
    Br J Haematol. 2024;204:945-958.
    >> Share

  292. SUN H, Zhu Y, Li J, Zhao L, et al
    CSF3R P733T is a deleterious germline variant in acute leukaemia showing gain-of-function-like T618I mutation.
    Br J Haematol. 2024;204:e31-e33.
    >> Share

  293. SHIMONY S, Chen EC
    Tri-ing to decipher trisomy AML.
    Br J Haematol. 2024;204:751-752.
    >> Share

  294. TAN JY, Yeo YH, Tan MC, Chavez JC, et al
    Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy.
    Br J Haematol. 2024;204:1114-1117.
    >> Share

  295. ZHAO HG
    Should oligomonocytic CMML be classified as an independent disease entity?
    Br J Haematol. 2024;204:749-750.
    >> Share

  296. LAM SSY, Tsui SP, Fung CY, Saw NY, et al
    Distinct karyotypic and mutational landscape in trisomy AML.
    Br J Haematol. 2024;204:939-944.
    >> Share

  297. COPLAND M, Ariti C, Thomas IF, Upton L, et al
    A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
    Br J Haematol. 2024;204:871-876.
    >> Share

  298. CASTANO-DIEZ S, Pomares H, Esteban D, Guijarro F, et al
    Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
    Br J Haematol. 2024;204:892-897.
    >> Share

  299. LU Q, Qu W, Wen Y, Ke P, et al
    Single-cell RNA-seq reveals the links between the metabolic heterogeneity and cell identity in NBM and AML.
    Br J Haematol. 2024;204:1100-1104.
    >> Share

  300. RAVANDI F, Dohner H, Wei AH, Montesinos P, et al
    Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
    Br J Haematol. 2024;204:877-886.
    >> Share

  301. MONTALBAN-BRAVO G, Jabbour E, Borthakur G, Kadia T, et al
    Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
    Br J Haematol. 2024;204:898-909.
    >> Share

  302. CHEN N, Pan J, Zhou Y, Mao L, et al
    Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;204:861-870.
    >> Share

    February 2024
  303. COSTA A, Breccia M
    How to improve treatment-free remission eligibility in chronic myeloid leukaemia?
    Br J Haematol. 2024;204:434-448.
    >> Share

  304. PARDANANI A, Reichard K, Tefferi A
    Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
    Br J Haematol. 2024;204:402-414.
    >> Share

  305. FUJI S, Yuda S, Tada Y, Kano M, et al
    A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post-transplant clinical outcome in patients with aggressive ATL.
    Br J Haematol. 2024;204:e25-e27.
    >> Share

  306. WANG Z, Fan Z, Wu Z, Xuan L, et al
    PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:628-637.
    >> Share

  307. KUMAR J, Ewalt MD, Zhang Y, Yao J, et al
    Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
    Br J Haematol. 2024;204:561-565.
    >> Share

  308. NYQUIST OE, Dalgaard J, Spetalen S, Torkildsen S, et al
    Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML.
    Br J Haematol. 2024;204:724-729.
    >> Share

  309. NARDOZZA AM, Guarnera L, Travaglini S, Ottone T, et al
    Characterization of a novel IDH2-R159H mutation in acute myeloid leukaemia: Effects on cell metabolism and differentiation.
    Br J Haematol. 2024;204:719-723.
    >> Share

  310. RAMAMOORTHY S, Lebrecht D, Schanze D, Schanze I, et al
    Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
    Br J Haematol. 2024;204:595-605.
    >> Share

  311. MARK C, Meshinchi S, Joyce B, Gibson B, et al
    Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias.
    Br J Haematol. 2024;204:576-584.
    >> Share

  312. SHEN Y, Freeman JA, Kerridge I, Downe P, et al
    Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL.
    Br J Haematol. 2024;204:487-491.
    >> Share

  313. BAI L, Zhang ZX, Hu GH, Cheng YF, et al
    Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre.
    Br J Haematol. 2024;204:585-594.
    >> Share

    January 2024
  314. MIYASHITA N, Onozawa M, Matsukawa T, Mori A, et al
    Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study.
    Br J Haematol. 2024 Jan 18. doi: 10.1111/bjh.19292.
    >> Share

  315. NAVRKALOVA V, Plevova K, Radova L, Porc J, et al
    Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naive CLL patients.
    Br J Haematol. 2024;204:240-249.
    >> Share

  316. HASSELBALCH HC, Skov V, Kjaer L, Larsen MK, et al
    Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
    Br J Haematol. 2024;204:16-18.
    >> Share

  317. GJERTSEN BT
    How to discover the exceptional venetoclax responders in AML/MDS?
    Br J Haematol. 2024;204:14-15.
    >> Share

  318. GESTRICH CK, De Lancy SJ, Kresak A, Meyerson H, et al
    IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:229-239.
    >> Share

  319. BARON F, Nagler A, Galimard JE, Sanz J, et al
    Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
    Br J Haematol. 2024;204:250-259.
    >> Share

  320. DE CASTRO FA, Mehdipour P, Chakravarthy A, Ettayebi I, et al
    Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia.
    Br J Haematol. 2024;204:206-220.
    >> Share

  321. NANAA A, He R, Foran JM, Badar T, et al
    Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
    Br J Haematol. 2024;204:171-176.
    >> Share

  322. MURPHY EL
    HTLV-1 and blood donation.
    Br J Haematol. 2024;204:29-30.
    >> Share

    December 2023
  323. HOKLAND P, Fernandez II, Freeman SD, Gjertsen BT, et al
    AML in the elderly-A global view.
    Br J Haematol. 2023;203:760-773.
    >> Share

  324. WU JF, Abid H, Szabo A, Abid MB, et al
    Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
    Br J Haematol. 2023;203:e117-e120.
    >> Share

  325. HERRITY E, Pereira MP, Kim DDH
    Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: Mechanistic diversity and therapeutic directions.
    Br J Haematol. 2023;203:722-735.
    >> Share

  326. MAHDI D, O'Nions J, Raj K, Baker R, et al
    Managing molecular relapse of acute myeloid leukaemia in early pregnancy: Is a watch and wait approach reasonable?
    Br J Haematol. 2023;203:e114-e116.
    >> Share

  327. QI P, Wang L, Li H, Wu Y, et al
    Venetoclax as a cytoreduction therapy for acute promyelocytic leukaemia: A single-centre experience.
    Br J Haematol. 2023;203:892-895.
    >> Share

  328. PERUSINI MA, Novitzky-Basso I, Atenafu EG, Forrest D, et al
    Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
    Br J Haematol. 2023;203:781-791.
    >> Share

  329. CHIRIAC R, Humbert C, Mejri A, Debliquis A, et al
    Charcot-Leyden crystals in acute myeloid leukaemia associated with basophilia.
    Br J Haematol. 2023;203:699-700.
    >> Share

    November 2023
  330. NG JY, Joshi M, Choi P
    Frequency and outcomes of obinutuzumab-induced thrombocytopenia.
    Br J Haematol. 2023;203:668-672.
    >> Share

  331. BORLENGHI E, Roccaro AM, Cattaneo C
    Rethinking the definition of 'less intensive' for venetoclax-combining regimens in acute myeloid leukaemia patients.
    Br J Haematol. 2023;203:504-506.
    >> Share

  332. REYNOLDS G, Urbancic KF, Fong CY, Trubiano JA, et al
    Invasive fungal infection following venetoclax and posaconazole co-administration.
    Br J Haematol. 2023;203:593-598.
    >> Share

  333. OCADLIKOVA D, Lussana F, Fracchiolla N, Bonifacio M, et al
    Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study.
    Br J Haematol. 2023;203:637-650.
    >> Share

  334. BOOTH E, Backx M, Joshi A, Nizami H, et al
    Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
    Br J Haematol. 2023;203:499-500.
    >> Share

  335. DONNETTE M, Hamimed M, Ciccolini J, Sicard G, et al
    Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
    Br J Haematol. 2023;203:625-636.
    >> Share

  336. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Li Z, Hammond D, et al
    Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
    Br J Haematol. 2023;203:581-592.
    >> Share

  337. APOLITO V, Arrigo G, Vasseur L, Olivi M, et al
    Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax.
    Br J Haematol. 2023;203:e98-e101.
    >> Share

  338. HILLS RK
    Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape.
    Br J Haematol. 2023;203:353-354.
    >> Share

  339. NOOR S, Haidary AM, Yosufzai AW, Niazai M, et al
    Demographic and clinical characteristics of acute myeloid leukaemia diagnosed and treated at the tertiary level in Afghanistan.
    Br J Haematol. 2023;203:404-410.
    >> Share

  340. MOIA R, Terzi di Bergamo L, Talotta D, Bomben R, et al
    XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.
    Br J Haematol. 2023;203:416-425.
    >> Share

    October 2023
  341. MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al
    The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170.
    >> Share

  342. PAN X, Chang Y, Ruan G, Wei F, et al
    Prognostic impact of FLT3-ITD mutation on NPM1(+) acute myeloid leukaemia patients and related molecular mechanisms.
    Br J Haematol. 2023;203:212-223.
    >> Share

  343. MAHDI D, Spiers J, Rampotas A, Polverelli N, et al
    Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
    Br J Haematol. 2023;203:169-181.
    >> Share

  344. SEVERIN F, Mouawad N, Ruggeri E, Visentin A, et al
    Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness.
    Br J Haematol. 2023;203:224-236.
    >> Share

  345. TRAVAGLINI S, Gurnari C, Antonelli S, Marchesi F, et al
    Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: A proof of concept.
    Br J Haematol. 2023;203:327-330.
    >> Share

  346. EADIE LN, Rehn JA, Schutz CE, Heatley SL, et al
    Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling.
    Br J Haematol. 2023;203:282-287.
    >> Share

  347. APOSTOLOVA P, Kreutmair S, Toffalori C, Punta M, et al
    Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response.
    Br J Haematol. 2023;203:264-281.
    >> Share

    September 2023
  348. BRECCIA M, Saglio G
    Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?
    Br J Haematol. 2023;202:1087-1088.
    >> Share

  349. HADDAD FG, Kourie HR, Saleh K
    Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2023;202:1084-1086.
    >> Share

  350. IRANI YD, Hughes A, Kok CH, Clarson J, et al
    Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
    Br J Haematol. 2023;202:1127-1136.
    >> Share

  351. FENG H, Fu Y, Cui Z, Zhou M, et al
    Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.
    Br J Haematol. 2023;202:1178-1191.
    >> Share

  352. PESCHKE JC, Bergmann R, Mehnert M, Gonzalez Soto KE, et al
    FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
    Br J Haematol. 2023;202:1137-1150.
    >> Share

  353. PASTORE F, Gittinger H, Raab S, Tschuri S, et al
    Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
    Br J Haematol. 2023;202:1165-1177.
    >> Share

  354. XIE M, Lu Y, Ouyang G, Li X, et al
    Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
    Br J Haematol. 2023;202:1119-1126.
    >> Share

  355. MATSUMOTO K, Kakazu N, Imataki O, Kondo A, et al
    Hairy cell leukaemia with an IGH-BRAF fusion gene.
    Br J Haematol. 2023;202:e67-e70.
    >> Share

  356. BELHADJ M, Burroni B, Kosmider O, Willems L, et al
    Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational study.
    Br J Haematol. 2023;202:e50-e53.
    >> Share

    August 2023
  357. KUSUDA M, Nakasone H, Yoshimura K, Okada Y, et al
    Gene expression and TCR amino acid sequences selected by HLA-A02:01-restricted CTLs specific to HTLV-1 in ATL patients.
    Br J Haematol. 2023;202:578-588.
    >> Share

  358. LOKE J, Upasani V, Gaskell C, Fox S, et al
    Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.
    Br J Haematol. 2023;202:498-503.
    >> Share

  359. SARTOR C, Brunetti L, Audisio E, Cignetti A, et al
    A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
    Br J Haematol. 2023;202:599-607.
    >> Share

  360. BORRILL R, Poulton K, Kusyk L, Routledge A, et al
    Granulocyte transfusion during cord blood transplant for relapsed, refractory AML is associated with massive CD8(+) T-cell expansion, significant cytokine release syndrome and induction of disease remission.
    Br J Haematol. 2023;202:589-598.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016